DE69401581D1 - Partikelförmiges vektor und pharmazeutische zusammensetzung die diese enthält - Google Patents

Partikelförmiges vektor und pharmazeutische zusammensetzung die diese enthält

Info

Publication number
DE69401581D1
DE69401581D1 DE69401581T DE69401581T DE69401581D1 DE 69401581 D1 DE69401581 D1 DE 69401581D1 DE 69401581 T DE69401581 T DE 69401581T DE 69401581 T DE69401581 T DE 69401581T DE 69401581 D1 DE69401581 D1 DE 69401581D1
Authority
DE
Germany
Prior art keywords
pct
pharmaceutical composition
sec
relates
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69401581T
Other languages
English (en)
Other versions
DE69401581T2 (de
Inventor
Pierre Perrin
Daniel Samain
Nathalie Castignolles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Biovector Therapeutics SA
Original Assignee
Institut Pasteur de Lille
Biovector Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille, Biovector Therapeutics SA filed Critical Institut Pasteur de Lille
Application granted granted Critical
Publication of DE69401581D1 publication Critical patent/DE69401581D1/de
Publication of DE69401581T2 publication Critical patent/DE69401581T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE69401581T 1993-04-21 1994-04-21 Partikelförmiges vektor und pharmazeutische zusammensetzung die diese enthält Expired - Fee Related DE69401581T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9304698A FR2704145B1 (fr) 1993-04-21 1993-04-21 Vecteur particulaire et composition pharmaceutique le contenant.
PCT/FR1994/000452 WO1994023701A1 (fr) 1993-04-21 1994-04-21 Vecteur particulaire et composition pharmaceutique le contenant

Publications (2)

Publication Number Publication Date
DE69401581D1 true DE69401581D1 (de) 1997-03-06
DE69401581T2 DE69401581T2 (de) 1997-08-21

Family

ID=9446283

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69401581T Expired - Fee Related DE69401581T2 (de) 1993-04-21 1994-04-21 Partikelförmiges vektor und pharmazeutische zusammensetzung die diese enthält

Country Status (8)

Country Link
US (1) US5891475A (de)
EP (1) EP0696191B1 (de)
JP (1) JPH08508990A (de)
AT (1) ATE147975T1 (de)
CA (1) CA2161121A1 (de)
DE (1) DE69401581T2 (de)
FR (1) FR2704145B1 (de)
WO (1) WO1994023701A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723849B1 (fr) * 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
FR2771929B1 (fr) * 1997-12-09 2001-02-23 Biovector Therapeutics Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de particules hydrophiles pour la delivrance d'agents actifs au systeme nerveux central
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
DE60003151T2 (de) * 1999-01-13 2004-04-08 Johns Hopkins University School Of Medicine Genetische immunisierung mit gleichzeitiger verabreichung von nukleinsäuren und zytokinen
JP2002543769A (ja) 1999-04-02 2002-12-24 コリクサ コーポレイション 肺癌の治療および診断のための化合物および方法
EP1721982B1 (de) 1999-04-15 2013-04-10 Boehringer Ingelheim Vetmedica GmbH Chimäre Nukleinsäuren und Polypeptide aus Iyssavirus
US6673601B1 (en) 1999-04-15 2004-01-06 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides
JP5502253B2 (ja) 2000-02-23 2014-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規化合物
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7238672B1 (en) 2000-04-17 2007-07-03 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides
US20030175700A1 (en) 2000-04-21 2003-09-18 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
FR2808194B1 (fr) * 2000-04-26 2004-05-07 Biovector Therapeutics Utilisation de particules hydrophiles portant ou non des ligands ioniques pour ameliorer les proprietes immunomodulatrices d'une substance autre qu'un antigene, et les compositions pharmaceutiques ainsi obtenues
EP1276468A1 (de) * 2000-04-26 2003-01-22 Biovector Therapeutics S.A. Verwendung teilchenförmiger vektoren in der immunomodulation
ES2333579T3 (es) 2000-06-20 2010-02-24 Corixa Corporation Proteinas de fusion de mycobacterium tuberculosis.
AU2001273149A1 (en) 2000-06-28 2002-01-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1515982A4 (de) 2001-05-09 2005-10-26 Corixa Corp Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
WO2003055469A1 (en) * 2001-12-21 2003-07-10 Celator Technologies Inc. Improved polymer-lipid delivery vehicles
CA2860702C (en) 2001-12-17 2019-02-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US20030235619A1 (en) * 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
SI1589934T1 (sl) 2003-01-06 2016-02-29 Corixa Corporation Corporation Service Company Določene aminoalkil glukozaminid fosfat spojine in njih uporaba
US6809197B1 (en) 2003-06-11 2004-10-26 Mgp Ingredients, Inc. Emulsion stabilizing starch products
US7381409B2 (en) 2003-06-16 2008-06-03 Celltech R&D, Inc. Antibodies specific for sclerostin and methods of screening and use therefor
CA2567597C (en) 2004-05-25 2014-03-18 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
US20080299205A1 (en) * 2004-07-19 2008-12-04 Mayer Lawrence D Particulate Constructs For Release of Active Agents
DK3312272T3 (da) 2004-10-08 2019-12-02 Us Gov Health & Human Services Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner
EP2392348A3 (de) 2005-03-31 2012-01-18 GlaxoSmithKline Biologicals S.A. Impfstoffe gegen Chlamydieninfektion
KR20150036658A (ko) 2005-04-29 2015-04-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
US8026354B2 (en) 2005-11-23 2011-09-27 Institut Pasteur Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use
WO2007082105A2 (en) 2006-01-16 2007-07-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chlamydia vaccine
EP1991257B1 (de) 2006-03-07 2015-05-06 Baxter International Inc. Hoch phosphorylierter und sulfatierter rekombinanter faktor ix
US8524454B2 (en) 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US8110226B2 (en) 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
AU2008342260B2 (en) 2007-12-27 2013-10-17 Baxter Healthcare S.A. Chemically modified Factor IX
ES2538007T3 (es) 2009-09-16 2015-06-16 Vaxart, Inc. Estrategia de inmunización para prevenir una infección por H1N1
EP2723365A1 (de) 2011-06-21 2014-04-30 Oncofactor Corporation Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
JP7448954B2 (ja) 2018-02-21 2024-03-13 ザ ユニバーシティー オブ モンタナ ジアリールトレハロース化合物及びその使用
WO2019169313A1 (en) 2018-03-02 2019-09-06 The University Of Montana Immunogenic trehalose compounds and uses thereof
KR20220018503A (ko) 2019-05-23 2022-02-15 더 유니버시티 오브 몬타나 Tlr 수용체 리간드에 기반한 백신 애주번트
EP4013788A1 (de) 2019-08-12 2022-06-22 Purinomia Biotech, Inc. Verfahren und zusammensetzungen zur förderung und verstärkung von t-zell-vermittelten immunantworten durch adcc-targeting von cd39-exprimierenden zellen
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2631826B1 (fr) * 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
JPH04503607A (ja) * 1989-02-24 1992-07-02 イムノセラピューティックス・インコーポレイテッド 固定化サイトカイン類
FR2677249B1 (fr) * 1991-06-04 1995-03-17 Biovecteurs As Vecteur particulaire biodegradable et procede de synthese.

Also Published As

Publication number Publication date
ATE147975T1 (de) 1997-02-15
EP0696191A1 (de) 1996-02-14
FR2704145B1 (fr) 1995-07-21
CA2161121A1 (fr) 1994-10-27
EP0696191B1 (de) 1997-01-22
DE69401581T2 (de) 1997-08-21
JPH08508990A (ja) 1996-09-24
FR2704145A1 (fr) 1994-10-28
WO1994023701A1 (fr) 1994-10-27
US5891475A (en) 1999-04-06

Similar Documents

Publication Publication Date Title
DE69401581D1 (de) Partikelförmiges vektor und pharmazeutische zusammensetzung die diese enthält
DE69115280D1 (de) Indolderivate, die die leukotrienbiosynthese hemmen.
DE68901955D1 (de) Insbesondere zum tragen von biologisch aktiven molekuelen geeignetes teilchenfoermiges vektorsystem und verfahren zu seiner herstellung.
TW286273B (de)
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
DE69413542T2 (de) Perhydroisoindolderivate als substanz p antagonisten
HUT77925A (hu) Dihidrobenzofuránok, azokat tartalmazó gyógyászati készítmények és eljárás előállításukra
ATE172735T1 (de) Tropyl 7-azaindol-3-ylcarboxamide als antitussivum
PL320167A1 (en) 2,2-dichloroalkanocarboxylic acids, method of obtaining them and therapeutic agents containing such compounds and their application in treating insulin immunity
ATE200672T1 (de) Alkoxyalkylcarbamate von imidazo(1,2-a)pyridinen
FI951511A0 (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
DK0909182T3 (da) Fremgangsmåde til fremstilling af chloriner og bakteriochloriner indeholdende polyether
AU1875395A (en) 4-amino derivatives of 5-substituted mycophenolic acid
ATE279521T1 (de) Regulierende nukleinsaeuresequenzen und verwendungen
GB9715177D0 (en) Medicament
AU2737095A (en) Monoclonal antibody active against cd44v6
IL117734A0 (en) Beta-carbolines and pharmaceutical compositions containing them
RU95100512A (ru) Мазь для лечения кожных заболеваний
MX9704978A (es) 5-aminopirazoles acilados y su empleo para la lucha contra las pestes animales.
IT1231058B (it) Dispositivo perfezionato per l'azionamento di corpi alternativamente mobili quali ad esempio accessori o componenti di giocattoli o articoli promozionali.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee